108th CONGRESS 2D Session

S.741

AN ACT

To amend the Federal Food, Drug, and Cosmetic Act with regard to new animal drugs, and for other purposes.

1 Be it enacted by the Senate and House of Representa-

2 tives of the United States of America in Congress assembled,

3 TITLE I—MINOR USE AND MINOR 4 SPECIES HEALTH

5 SECTION 101. SHORT TITLE.

6 This title may be cited as the "Minor Use and Minor7 Species Animal Health Act of 2004".

 $\mathbf{2}$

3 (a) FINDINGS.—Congress makes the following find-4 ings:

5 (1) There is a severe shortage of approved new6 animal drugs for use in minor species.

7 (2) There is a severe shortage of approved new
8 animal drugs for treating animal diseases and condi9 tions that occur infrequently or in limited geographic
10 areas.

(3) Because of the small market shares, lowprofit margins involved, and capital investment required, it is generally not economically feasible for
new animal drug applicants to pursue approvals for
these species, diseases, and conditions.

(4) Because the populations for which such new
animal drugs are intended may be small and conditions of animal management may vary widely, it is
often difficult to design and conduct studies to establish drug safety and effectiveness under traditional new animal drug approval processes.

(5) It is in the public interest and in the interest of animal welfare to provide for special procedures to allow the lawful use and marketing of certain new animal drugs for minor species and minor
uses that take into account these special cir-

1	cumstances and that ensure that such drugs do not
2	endanger animal or public health.
3	(6) Exclusive marketing rights for clinical test-
4	ing expenses have helped encourage the development
5	of "orphan" drugs for human use, and comparable
6	incentives should encourage the development of new
7	animal drugs for minor species and minor uses.
8	(b) Amendments to the Federal Food, Drug,
9	and Cosmetic Act.—
10	(1) Definitions.—Section 201 of the Federal,
11	Food, Drug, and Cosmetic Act (21 U.S.C. 321) is
12	amended by adding at the end the following:
13	"(nn) The term 'major species' means cattle, horses,
14	swine, chickens, turkeys, dogs, and cats, except that the
15	Secretary may add species to this definition by regulation.
16	"(00) The term 'minor species' means animals other
17	than humans that are not major species.
18	"(pp) The term 'minor use' means the intended use
19	of a drug in a major species for an indication that occurs
20	infrequently and in only a small number of animals or in
21	limited geographical areas and in only a small number of
22	animals annually.".
23	(2) Three-year exclusivity for minor use
24	AND MINOR SPECIES APPROVALS.—Section
25	512(c)(2)(F) (ii), (iii), and (v) of the Federal Food,

3

1 Drug, and Cosmetic Act is amended by striking 2 "(other than bioequivalence or residue studies)" and 3 inserting "(other than bioequivalence studies or res-4 idue depletion studies, except residue depletion stud-5 ies for minor uses or minor species)" every place it 6 appears.

7 (3) SCOPE OF REVIEW FOR MINOR USE AND
8 MINOR SPECIES APPLICATIONS.—Section 512(d) of
9 the Federal Food, Drug, and Cosmetic Act is
10 amended by adding at the end the following new
11 paragraph:

12 "(5) In reviewing an application that proposes 13 a change to add an intended use for a minor use or 14 a minor species to an approved new animal drug ap-15 plication, the Secretary shall reevaluate only the rel-16 evant information in the approved application to de-17 termine whether the application for the minor use or 18 minor species can be approved. A decision to ap-19 prove the application for the minor use or minor 20 species is not, implicitly or explicitly, a reaffirmation 21 of the approval of the original application.".

(4) MINOR USE AND MINOR SPECIES NEW ANIMAL
DRUGS.—Chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended by adding
at the end the following:

3 "SEC. 571. CONDITIONAL APPROVAL OF NEW ANIMAL 4 DRUGS FOR MINOR USE AND MINOR SPECIES.

5 "(a)(1) Except as provided in paragraph (3) of this section, any person may file with the Secretary an applica-6 7 tion for conditional approval of a new animal drug in-8 tended for a minor use or a minor species. Such an appli-9 cation may not be a supplement to an application ap-10 proved under section 512. Such application must comply in all respects with the provisions of section 512 of this 11 12 Act except sections 512(a)(4), 512(b)(2), 512(c)(1), 512(c)(2), 512(c)(3), 512(d)(1), 512(e), 512(h), and 13 512(n) unless otherwise stated in this section, and any ad-14 15 ditional provisions of this section. New animal drugs are subject to application of the same safety standards that 16 would be applied to such drugs under section 512(d) (in-17 cluding, for antimicrobial new animal drugs, with respect 18 to antimicrobial resistance). 19

20 "(2) The applicant shall submit to the Secretary as
21 part of an application for the conditional approval of a
22 new animal drug—

23 "(A) all information necessary to meet the re24 quirements of section 512(b)(1) except section
25 512(b)(1)(A);

	0
1	"(B) full reports of investigations which have
2	been made to show whether or not such drug is safe
3	under section 512(d) (including, for an antimicrobial
4	new animal drug, with respect to antimicrobial re-
5	sistance) and there is a reasonable expectation of ef-
6	fectiveness for use;
7	"(C) data for establishing a conditional dose;
8	"(D) projections of expected need and the jus-
9	tification for that expectation based on the best in-
10	formation available;
11	"(E) information regarding the quantity of
12	drug expected to be distributed on an annual basis
13	to meet the expected need; and
14	"(F) a commitment that the applicant will con-
15	duct additional investigations to meet the require-
16	ments for the full demonstration of effectiveness
17	under section $512(d)(1)(E)$ within 5 years.
18	$\ensuremath{^{\prime\prime}}(3)$ A person may not file an application under para-
19	graph (1) if—
20	"(A) the application seeks conditional approval
21	of a new animal drug that is contained in, or is a
22	product of, a transgenic animal.
23	"(B) the person has previously filed an applica-
24	tion for conditional approval under paragraph (1)
25	for the same drug in the same dosage form for the

same intended use whether or not subsequently con ditionally approved by the Secretary under sub section (b), or

4 "(C) the person obtained the application, or
5 data or other information contained therein, directly
6 or indirectly from the person who filed for condi7 tional approval under paragraph (1) for the same
8 drug in the same dosage form for the same intended
9 use whether or not subsequently conditionally ap10 proved by the Secretary under subsection (b).

"(b) Within 180 days after the filing of an application pursuant to subsection (a), or such additional period
as may be agreed upon by the Secretary and the applicant,
the Secretary shall either—

"(1) issue an order, effective for one year, conditionally approving the application if the Secretary
finds that none of the grounds for denying conditional approval, specified in subsection (c) of this
section applies and publish a Federal Register notice
of the conditional approval, or

21 "(2) give the applicant notice of an opportunity
22 for an informal hearing on the question whether
23 such application can be conditionally approved.

24 "(c) If the Secretary finds, after giving the applicant25 notice and an opportunity for an informal hearing, that—

1 "(1) any of the provisions of section 512(d)(1)2 (A) through (D) or (F) through (I) are applicable; "(2) the information submitted to the Secretary 3 4 as part of the application and any other information 5 before the Secretary with respect to such drug, is in-6 sufficient to show that there is a reasonable expecta-7 tion that the drug will have the effect it purports or 8 is represented to have under the conditions of use 9 prescribed, recommended, or suggested in the pro-10 posed labeling thereof; or

11 "(3) another person has received approval 12 under section 512 for the same drug in the same 13 dosage form for the same intended use, and that 14 person is able to assure the availability of sufficient 15 quantities of the drug to meet the needs for which 16 the drug is intended;

the Secretary shall issue an order refusing to conditionally 17 18 approve the application. If, after such notice and oppor-19 tunity for an informal hearing, the Secretary finds that paragraphs (1) through (3) do not apply, the Secretary 20 21 shall issue an order conditionally approving the application 22 effective for one year and publish a Federal Register no-23 tice of the conditional approval. Any order issued under 24 this subsection refusing to conditionally approve an appli-25 cation shall state the findings upon which it is based.

1 "(d) A conditional approval under this section is ef-2 fective for a 1-year period and is thereafter renewable by 3 the Secretary annually for up to 4 additional 1-year terms. 4 A conditional approval shall be in effect for no more than 5 5 years from the date of approval under subsection (b)(1)6 or (c) of this section unless extended as provided for in 7 subsection (h) of this section. The following shall also 8 apply:

9 "(1) No later than 90 days from the end of the 10 1-year period for which the original or renewed con-11 ditional approval is effective, the applicant may sub-12 mit a request to renew a conditional approval for an 13 additional 1-year term.

14 "(2) A conditional approval shall be deemed re-15 newed at the end of the 1-year period, or at the end 16 of a 90-day extension that the Secretary may, at the 17 Secretary's discretion, grant by letter in order to 18 complete review of the renewal request, unless the 19 Secretary determines before the expiration of the 1-20 year period or the 90-day extension that—

21 "(A) the applicant failed to submit a time-22 ly renewal request;

23 "(B) the request fails to contain sufficient
24 information to show that—

10

1	"(i) the applicant is making sufficient
2	progress toward meeting approval require-
3	ments under section $512(d)(1)(E)$, and is
4	likely to be able to fulfill those require-
5	ments and obtain an approval under sec-
6	tion 512 before the expiration of the 5-year
7	maximum term of the conditional approval;
8	"(ii) the quantity of the drug that has
9	been distributed is consistent with the con-
10	ditionally approved intended use and condi-
11	tions of use, unless there is adequate ex-
12	planation that ensures that the drug is
13	only used for its intended purpose; or
14	"(iii) the same drug in the same dos-
15	age form for the same intended use has
16	not received approval under section 512, or
17	if such a drug has been approved, that the
18	holder of the approved application is un-
19	able to assure the availability of sufficient
20	quantities of the drug to meet the needs
21	for which the drug is intended; or
22	"(C) any of the provisions of section
23	512(e)(1) (A) through (B) or (D) through (F)
24	are applicable.
23	512(e)(1) (A) through (B) or (D) through

1 "(3) If the Secretary determines before the end 2 of the 1-year period or the 90-day extension, if 3 granted, that a conditional approval should not be 4 renewed, the Secretary shall issue an order refusing 5 to renew the conditional approval, and such condi-6 tional approval shall be deemed withdrawn and no 7 longer in effect. The Secretary shall thereafter pro-8 vide an opportunity for an informal hearing to the 9 applicant on the issue whether the conditional ap-10 proval shall be reinstated.

"(e)(1) The Secretary shall issue an order with-11 12 drawing conditional approval of an application filed pursu-13 ant to subsection (a) if the Secretary finds that another person has received approval under section 512 for the 14 15 same drug in the same dosage form for the same intended use and that person is able to assure the availability of 16 17 sufficient quantities of the drug to meet the needs for 18 which the drug is intended.

"(2) The Secretary shall, after due notice and opportunity for an informal hearing to the applicant, issue an
order withdrawing conditional approval of an application
filed pursuant to subsection (a) if the Secretary finds
that—

"(A) any of the provisions of section 512(e)(1)
 (A) through (B) or (D) through (F) are applicable;
 or

"(B) on the basis of new information before the 4 5 Secretary with respect to such drug, evaluated to-6 gether with the evidence available to the Secretary 7 when the application was conditionally approved, 8 that there is not a reasonable expectation that such 9 drug will have the effect it purports or is rep-10 resented to have under the conditions of use pre-11 scribed, recommended, or suggested in the labeling 12 thereof.

"(3) The Secretary may also, after due notice and
opportunity for an informal hearing to the applicant, issue
an order withdrawing conditional approval of an application filed pursuant to subsection (a) if the Secretary finds
that any of the provisions of section 512(e)(2) are applicable.

19 "(f)(1) The label and labeling of a new animal drug20 with a conditional approval under this section shall—

21 "(A) bear the statement, 'conditionally ap22 proved by FDA pending a full demonstration of ef23 fectiveness under application number'; and

24 "(B) contain such other information as pre-25 scribed by the Secretary.

"(2) An intended use that is the subject of a condi tional approval under this section shall not be included
 in the same product label with any intended use approved
 under section 512.

5 "(g) A conditionally approved new animal drug appli6 cation may not be amended or supplemented to add indi7 cations for use.

8 "(h) 180 days prior to the termination date estab-9 lished under subsection (d) of this section, an applicant 10 shall have submitted all the information necessary to sup-11 port a complete new animal drug application in accordance 12 with section 512(b)(1) or the conditional approval issued 13 under this section is no longer in effect. Following review 14 of this information, the Secretary shall either—

"(1) issue an order approving the application
under section 512(c) if the Secretary finds that none
of the grounds for denying approval specified in section 512(d)(1) applies, or

"(2) give the applicant an opportunity for a
hearing before the Secretary under section 512(d)
on the question whether such application can be approved.

23 Upon issuance of an order approving the application,24 product labeling and administrative records of approval25 shall be modified accordingly. If the Secretary has not

issued an order under section 512(c) approving such appli-1 2 cation prior to the termination date established under sub-3 section (d) of this section, the conditional approval issued 4 under this section is no longer in effect unless the Sec-5 retary grants an extension of an additional 180-day period so that the Secretary can complete review of the applica-6 7 tion. The decision to grant an extension is committed to 8 the discretion of the Secretary and not subject to judicial 9 review.

"(i) The decision of the Secretary under subsection
(c), (d), or (e) of this section refusing or withdrawing conditional approval of an application shall constitute final
agency action subject to judicial review.

14 "(j) In this section and section 572, the term 15 'transgenic animal' means an animal whose genome con-16 tains a nucleotide sequence that has been intentionally 17 modified in vitro, and the progeny of such an animal; Pro-18 vided that the term 'transgenic animal' does not include 19 an animal of which the nucleotide sequence of the genome 20 has been modified solely by selective breeding.

21 "SEC. 572. INDEX OF LEGALLY MARKETED UNAPPROVED
22 NEW ANIMAL DRUGS FOR MINOR SPECIES.
23 "(a)(1) The Secretary shall establish an index limited

24 to-

"(A) new animal drugs intended for use in a
minor species for which there is a reasonable certainty that the animal or edible products from the
animal will not be consumed by humans or food-producing animals; and

6 "(B) new animal drugs intended for use only in 7 a hatchery, tank, pond, or other similar contained 8 man-made structure in an early, non-food life stage 9 of a food-producing minor species, where safety for 10 humans is demonstrated in accordance with the 11 standard of section 512(d) (including, for an anti-12 microbial new animal drug, with respect to anti-13 microbial resistance).

"(2) The index shall not include a new animal drug
that is contained in or a product of a transgenic animal.
"(b) Any person intending to file a request under this
section shall be entitled to one or more conferences to discuss the requirements for indexing a new animal drug.

"(c)(1) Any person may submit a request to the Secretary for a determination whether a new animal drug
may be eligible for inclusion in the index. Such a request
shall include—

23 "(A) information regarding the need for the
24 new animal drug, the species for which the new ani25 mal drug is intended, the proposed intended use and

conditions of use, and anticipated annual distribu tion;

3 "(B) information to support the conclusion that
4 the proposed use meets the conditions of subpara5 graph (A) or (B) of subsection (a)(1) of this section;
6 "(C) information regarding the components and
7 composition of the new animal drug;

8 "(D) a description of the methods used in, and
9 the facilities and controls used for, the manufacture,
10 processing, and packing of such new animal drug;

11 "(E) an environmental assessment that meets 12 the requirements of the National Environmental Pol-13 icy Act of 1969, as amended, and as defined in 21 14 CFR Part 25, as it appears on the date of enact-15 ment of this provision and amended thereafter or in-16 formation to support a categorical exclusion from 17 the requirement to prepare an environmental assess-18 ment;

"(F) information sufficient to support the conclusion that the proposed use of the new animal
drug is safe under section 512(d) with respect to individuals exposed to the new animal drug through
its manufacture or use; and

"(G) such other information as the Secretary
 may deem necessary to make this eligibility deter mination.

"(2) Within 90 days after the submission of a request 4 for a determination of eligibility for indexing based on sub-5 section (a)(1)(A) of this section, or 180 days for a request 6 7 submitted based on subsection (a)(1)(B) of this section, 8 the Secretary shall grant or deny the request, and notify 9 the person who requested such determination of the Secretary's decision. The Secretary shall grant the request if 10 11 the Secretary finds that—

12 "(A) the same drug in the same dosage form
13 for the same intended use is not approved or condi14 tionally approved;

"(B) the proposed use of the drug meets the
conditions of subparagraph (A) or (B) of subsection
(a)(1), as appropriate;

18 "(C) the person requesting the determination 19 has established appropriate specifications for the 20 manufacture and control of the new animal drug 21 and has demonstrated an understanding of the re-22 quirements of current good manufacturing practices; 23 "(D) the new animal drug will not significantly 24 affect the human environment; and "(E) the new animal drug is safe with respect
 to individuals exposed to the new animal drug
 through its manufacture or use.

4 If the Secretary denies the request, the Secretary shall 5 thereafter provide due notice and an opportunity for an informal conference. A decision of the Secretary to deny 6 7 an eligibility request following an informal conference shall 8 constitute final agency action subject to judicial review. 9 ((d)(1)) With respect to a new animal drug for which the Secretary has made a determination of eligibility 10 under subsection (c), the person who made such a request 11 12 may ask that the Secretary add the new animal drug to the index established under subsection (a). The request 13 14 for addition to the index shall include—

15 "(A) a copy of the Secretary's determination of
16 eligibility issued under subsection (c);

17 "(B) a written report that meets the require-18 ments in subsection (d)(2) of this section;

19 "(C) a proposed index entry;

20 "(D) facsimile labeling;

21 "(E) anticipated annual distribution of the new22 animal drug;

23 "(F) a written commitment to manufacture the24 new animal drug and animal feeds bearing or con-

1	taining such new animal drug according to current
2	good manufacturing practices;
3	"(G) a written commitment to label, distribute,
4	and promote the new animal drug only in accordance
5	with the index entry;
6	"(H) upon specific request of the Secretary, in-
7	formation submitted to the expert panel described in
8	paragraph (3); and
9	"(I) any additional requirements that the Sec-
10	retary may prescribe by general regulation or spe-
11	cific order.
12	"(2) The report required in paragraph (1) shall—
13	"(A) be authored by a qualified expert panel;
14	"(B) include an evaluation of all available tar-
15	get animal safety and effectiveness information, in-
16	cluding anecdotal information;
17	"(C) state the expert panel's opinion regarding
18	whether the benefits of using the new animal drug
19	for the proposed use in a minor species outweigh its
20	risks to the target animal, taking into account the
21	harm being caused by the absence of an approved or
22	conditionally approved new animal drug for the
23	minor species in question;
24	"(D) include information from which labeling
25	can be written; and

1

2

"(E) include a recommendation regarding

whether the new animal drug should be limited to

3	use under the professional supervision of a licensed
4	veterinarian.
5	$\ensuremath{^{\prime\prime}}(3)$ A qualified expert panel, as used in this section,
6	is a panel that—
7	"(A) is composed of experts qualified by sci-
8	entific training and experience to evaluate the target
9	animal safety and effectiveness of the new animal
10	drug under consideration;
11	"(B) operates external to FDA; and
12	"(C) is not subject to the Federal Advisory
13	Committee Act, 5 U.S.C. App. 2.
14	The Secretary shall define the criteria for selection of a
15	qualified expert panel and the procedures for the operation
16	of the panel by regulation.
17	"(4) Within 180 days after the receipt of a request
18	for listing a new animal drug in the index, the Secretary
19	shall grant or deny the request. The Secretary shall grant
20	the request if the request for indexing continues to meet
21	the eligibility criteria in subsection (a) and the Secretary
22	finds, on the basis of the report of the qualified expert
23	panel and other information available to the Secretary,
24	that the benefits of using the new animal drug for the
25	proposed use in a minor species outweigh its risks to the

target animal, taking into account the harm caused by the 1 2 absence of an approved or conditionally-approved new animal drug for the minor species in question. If the Sec-3 4 retary denies the request, the Secretary shall thereafter provide due notice and the opportunity for an informal 5 conference. The decision of the Secretary following an in-6 formal conference shall constitute final agency action sub-7 8 ject to judicial review.

9 "(e)(1) The index established under subsection (a)
10 shall include the following information for each listed
11 drug—

12 "(A) the name and address of the person whoholds the index listing;

14 "(B) the name of the drug and the intended
15 use and conditions of use for which it is being in16 dexed;

17 "(C) product labeling; and

18 "(D) conditions and any limitations that the
19 Secretary deems necessary regarding use of the
20 drug.

21 "(2) The Secretary shall publish the index, and revise22 it periodically.

23 "(3) The Secretary may establish by regulation a
24 process for reporting changes in the conditions of manu25 facturing or labeling of indexed products.

1	$^{\prime\prime}(f)(1)$ If the Secretary finds, after due notice to the
2	person who requested the index listing and an opportunity
3	for an informal conference, that—
4	"(A) the expert panel failed to meet the re-
5	quirements as set forth by the Secretary by regula-
6	tion;
7	"(B) on the basis of new information before the
8	Secretary, evaluated together with the evidence
9	available to the Secretary when the new animal drug
10	was listed in the index, the benefits of using the new
11	animal drug for the indexed use do not outweigh its
12	risks to the target animal;
13	"(C) the conditions of subsection $(c)(2)$ of this
14	section are no longer satisfied;
15	"(D) the manufacture of the new animal drug
16	is not in accordance with current good manufac-
17	turing practices;
18	"(E) the labeling, distribution, or promotion of
19	the new animal drug is not in accordance with the
20	index entry;
21	"(F) the conditions and limitations of use asso-
22	ciated with the index listing have not been followed;
23	or
24	"(G) the request for indexing contains any un-
25	true statement of material fact,

the Secretary shall remove the new animal drug from the
 index. The decision of the Secretary following an informal
 conference shall constitute final agency action subject to
 judicial review.

5 "(2) If the Secretary finds that there is a reasonable
6 probability that the use of the drug would present a risk
7 to the health of humans or other animals, the Secretary
8 may—

9 "(A) suspend the listing of such drug imme-10 diately;

11 "(B) give the person listed in the index prompt12 notice of the Secretary's action; and

13 "(C) afford that person the opportunity for an14 informal conference.

15 The decision of the Secretary following an informal con-16 ference shall constitute final agency action subject to judi-17 cial review.

18 "(g) For purposes of indexing new animal drugs under this section, to the extent consistent with the public 19 20 health, the Secretary shall promulgate regulations for ex-21 empting from the operation of section 512 minor species 22 new animal drugs and animal feeds bearing or containing 23 new animal drugs intended solely for investigational use 24 by experts qualified by scientific training and experience to investigate the safety and effectiveness of minor species 25

animal drugs. Such regulations may, at the discretion of 1 2 the Secretary, among other conditions relating to the pro-3 tection of the public health, provide for conditioning such 4 exemption upon the establishment and maintenance of 5 such records, and the making of such reports to the Secretary, by the manufacturer or the sponsor of the inves-6 7 tigation of such article, of data (including but not limited 8 to analytical reports by investigators) obtained as a result 9 of such investigational use of such article, as the Secretary 10 finds will enable the Secretary to evaluate the safety and 11 effectiveness of such article in the event of the filing of 12 a request for an index listing pursuant to this section.

13 "(h) The labeling of a new animal drug that is the
14 subject of an index listing shall state, prominently and
15 conspicuously—

16 "(1) 'NOT APPROVED BY FDA.—Legally mar17 keted as an FDA indexed product. Extra-label use
18 is prohibited.';

"(2) except in the case of new animal drugs indexed for use in an early life stage of a food-producing animal, 'This product is not to be used in
animals intended for use as food for humans or
other animals.'; and

24 "(3) such other information as may be pre-25 scribed by the Secretary in the index listing.

1 "(i)(1) In the case of any new animal drug for which 2 an index listing pursuant to subsection (a) is in effect, 3 the person who has an index listing shall establish and 4 maintain such records, and make such reports to the Sec-5 retary, of data relating to experience, and other data or information, received or otherwise obtained by such person 6 7 with respect to such drug, or with respect to animal feeds 8 bearing or containing such drug, as the Secretary may by 9 general regulation, or by order with respect to such listing, 10 prescribe on the basis of a finding that such records and reports are necessary in order to enable the Secretary to 11 12 determine, or facilitate a determination, whether there is 13 or may be ground for invoking subsection (f). Such regulation or order shall provide, where the Secretary deems it 14 15 to be appropriate, for the examination, upon request, by the persons to whom such regulation or order is applica-16 ble, of similar information received or otherwise obtained 17 by the Secretary. 18

19 "(2) Every person required under this subsection to 20 maintain records, and every person in charge or custody 21 thereof, shall, upon request of an officer or employee des-22 ignated by the Secretary, permit such officer or employee 23 at all reasonable times to have access to and copy and 24 verify such records. "(j)(1) Safety and effectiveness data and information
 which has been submitted in support of a request for a
 new animal drug to be indexed under this section and
 which has not been previously disclosed to the public shall
 be made available to the public, upon request, unless ex traordinary circumstances are shown—

7 "(A) if no work is being or will be undertaken
8 to have the drug indexed in accordance with the re9 quest,

"(B) if the Secretary has determined that such
drug cannot be indexed and all legal appeals have
been exhausted,

13 "(C) if the indexing of such drug is terminated14 and all legal appeals have been exhausted, or

15 "(D) if the Secretary has determined that such16 drug is not a new animal drug.

"(2) Any request for data and information pursuant
to paragraph (1) shall include a verified statement by the
person making the request that any data or information
received under such paragraph shall not be disclosed by
such person to any other person—

"(A) for the purpose of, or as part of a plan,
scheme, or device for, obtaining the right to make,
use, or market, or making, using, or marketing, out-

1	side the United States, the drug identified in the re-
2	quest for indexing; and
3	"(B) without obtaining from any person to
4	whom the data and information are disclosed an
5	identical verified statement, a copy of which is to be
6	provided by such person to the Secretary, which
7	meets the requirements of this paragraph.
8	"SEC. 573. DESIGNATED NEW ANIMAL DRUGS FOR MINOR
9	USE OR MINOR SPECIES.
10	"(a) DESIGNATION.—
11	((1) The manufacturer or the sponsor of a new
12	animal drug for a minor use or use in a minor spe-
13	cies may request that the Secretary declare that
14	drug a 'designated new animal drug'. A request for
15	designation of a new animal drug shall be made be-
16	fore the submission of an application under section
17	512(b) or section 571 for the new animal drug.
18	"(2) The Secretary may declare a new animal
19	drug a 'designated new animal drug' if—
20	"(A) it is intended for a minor use or use
21	in a minor species; and
22	"(B) the same drug in the same dosage
23	form for the same intended use is not approved
24	under section 512 or 571 or designated under
25	this section at the time the request is made.

1 "(3) Regarding the termination of a 2 designation—

"(A) the sponsor of a new animal drug
shall notify the Secretary of any decision to discontinue active pursuit of approval under section 512 or 571 of an application for a designated new animal drug. The Secretary shall
terminate the designation upon such notification;

"(B) the Secretary may also terminate designation if the Secretary independently determines that the sponsor is not actively pursuing
approval under section 512 or 571 with due
diligence;

"(C) the sponsor of an approved designated new animal drug shall notify the Secretary of any discontinuance of the manufacture of such new animal drug at least one year
before discontinuance. The Secretary shall terminate the designation upon such notification;
and

22 "(D) the designation shall terminate upon
23 the expiration of any applicable exclusivity pe24 riod under subsection (c).

28

	_0
1	"(4) Notice respecting the designation or termi-
2	nation of designation of a new animal drug shall be
3	made available to the public.
4	"(b) Grants and Contracts for Development
5	of Designated New Animal Drugs.—
6	"(1) The Secretary may make grants to and
7	enter into contracts with public and private entities
8	and individuals to assist in defraying the costs of
9	qualified safety and effectiveness testing expenses
10	and manufacturing expenses incurred in connection
11	with the development of designated new animal
12	drugs.
13	"(2) For purposes of paragraph (1) of this
14	section—
15	"(A) The term 'qualified safety and effec-
16	tiveness testing' means testing—
17	"(i) which occurs after the date such
18	new animal drug is designated under this
19	section and before the date on which an
20	application with respect to such drug is
21	submitted under section 512; and
22	"(ii) which is carried out under an in-
23	vestigational exemption under section
24	512(j).

"(B) The term 'manufacturing expenses' 1 2 means expenses incurred in developing processes and procedures associated with manufac-3 4 ture of the designated new animal drug which 5 occur after the new animal drug is designated 6 under this section and before the date on which 7 an application with respect to such new animal 8 drug is submitted under section 512 or 571.

9 "(c) EXCLUSIVITY FOR DESIGNATED NEW ANIMAL
10 DRUGS.—

11 "(1) Except as provided in subsection (c)(2), if 12 the Secretary approves or conditionally approves an 13 application for a designated new animal drug, the 14 Secretary may not approve or conditionally approve 15 another application submitted for such new animal drug with the same intended use as the designated 16 17 new animal drug for another applicant before the ex-18 piration of seven years from the date of approval or 19 conditional approval of the application.

"(2) If an application filed pursuant to section
512 or section 571 is approved for a designated new
animal drug, the Secretary may, during the 7-year
exclusivity period beginning on the date of the application approval or conditional approval, approve or
conditionally approve another application under sec-

tion 512 or section 571 for such drug for such
minor use or minor species for another applicant
if—

"(A) the Secretary finds, after providing 4 the holder of such an approved application no-5 6 tice and opportunity for the submission of 7 views, that in the granted exclusivity period the 8 holder of the approved application cannot as-9 sure the availability of sufficient quantities of 10 the drug to meet the needs for which the drug 11 was designated; or

"(B) such holder provides written consent
to the Secretary for the approval or conditional
approval of other applications before the expiration of such exclusivity period.".

16 (5) CONFORMING AMENDMENTS.—

17 (A) Section 201(u) of the Federal Food,
18 Drug, and Cosmetic Act is amended by striking
19 "512" and inserting "512, 571".

20 (B) Section 201(v) of the Federal Food,
21 Drug, and Cosmetic Act is amended by insert22 ing the following after paragraph (2): "Pro23 vided that any drug intended for minor use or
24 use in a minor species that is not the subject
25 of a final regulation published by the Secretary

1	through notice and comment rulemaking find-
2	ing that the criteria of paragraphs (1) and (2)
3	have not been met (or that the exception to the
4	criterion in paragraph (1) has been met) is a
5	new animal drug.".
6	(C) Section 301(e) of the Federal Food,
7	Drug, and Cosmetic Act is amended by striking
8	(512(a)(4)(C), 512(j), (l) or (m)" and inserting)
9	" $512(a)(4)(C)$, $512(j)$, (l) or (m), $572(i)$."
10	(D) Section 301(j) of the Federal Food,
11	Drug, and Cosmetic Act is amended by striking
12	"520" and inserting "520, 571, 572, 573."
13	(E) Section 502 of the Federal Food,
14	Drug, and Cosmetic Act is amended by adding
15	at the end the following new subsection:
16	"(w) If it is a new animal drug—
17	"(1) that is conditionally approved under sec-
18	tion 571 and its labeling does not conform with the
19	approved application or section 571(f), or that is not
20	conditionally approved under section 571 and its
21	label bears the statement set forth in section
22	571(f)(1)(A); or
23	"(2) that is indexed under section 572 and its
24	labeling does not conform with the index listing
25	under section 572(e) or 572(h), or that has not been

1	indexed under section 572 and its label bears the
2	statement set forth in section 572(h).".
3	(F) Section 503(f) of the Federal Food,
4	Drug, and Cosmetic Act is amended—
5	(i) in paragraph (1)(A)(ii) by striking
6	"512" and inserting "512, a conditionally-
7	approved application under section 571, or
8	an index listing under section 572"; and
9	(ii) in paragraph (3) by striking "sec-
10	tion 512" and inserting "section 512, 571,
11	or 572".
12	(G) Section $504(a)(1)$ of the Federal Food,
13	Drug, and Cosmetic Act is amended by striking
14	"512(b)" and inserting "512(b), a condi-
15	tionally-approved application filed pursuant to
16	section 571, or an index listing pursuant to sec-
17	tion 572".
18	(H) Sections $504(a)(2)(B)$ and $504(b)$ of
19	the Federal Food, Drug, and Cosmetic Act are
20	amended by striking "512(i)" each place it ap-
21	pears and inserting "512(i), or the index listing
22	pursuant to section 572(e)".
23	(I) Section 512(a) of the Federal Food,
24	Drug, and Cosmetic Act is amended by striking

paragraphs (1) and (2) and inserting the following:

3 "(1) A new animal drug shall, with respect to any
4 particular use or intended use of such drug, be deemed
5 unsafe for purposes of section 501(a)(5) and section
6 402(a)(2)(C)(ii) unless—

"(A) there is in effect an approval of an application filed pursuant to subsection (b) with respect
to such use or intended use of such drug, and such
drug, its labeling, and such use conform to such approved application;

12 "(B) there is in effect a conditional approval of 13 an application filed pursuant to section 571 with re-14 spect to such use or intended use of such drug, and 15 such drug, its labeling, and such use conform to 16 such conditionally approved application; or

"(C) there is in effect an index listing pursuant
to section 572 with respect to such use or intended
use of such drug in a minor species, and such drug,
its labeling, and such use conform to such index listing.

A new animal drug shall also be deemed unsafe for such
purposes in the event of removal from the establishment
of a manufacturer, packer, or distributor of such drug for
use in the manufacture of animal feed in any State unless

1

2

at the time of such removal such manufacturer, packer, 1 2 or distributor has an unrevoked written statement from 3 the consignee of such drug, or notice from the Secretary, 4 to the effect that, with respect to the use of such drug 5 in animal feed, such consignee (i) holds a license issued under subsection (m) and has in its possession current ap-6 7 proved labeling for such drug in animal feed; or (ii) will, 8 if the consignee is not a user of the drug, ship such drug 9 only to a holder of a license issued under subsection (m). 10 "(2) An animal feed bearing or containing a new ani-

11 mal drug shall, with respect to any particular use or in12 tended use of such animal feed be deemed unsafe for pur13 poses of section 501(a)(6) unless—

14 "(A) there is in effect—

"(i) an approval of an application filed
pursuant to subsection (b) with respect to such
drug, as used in such animal feed, and such
animal feed and its labeling, distribution, holding, and use conform to such approved application;

21 "(ii) a conditional approval of an applica22 tion filed pursuant to section 571 with respect
23 to such drug, as used in such animal feed, and
24 such animal feed and its labeling, distribution,

1	holding, and use conform to such conditionally
2	approved application; or
3	"(iii) an index listing pursuant to section
4	572 with respect to such drug, as used in such
5	animal feed, and such animal feed and its label-
6	ing, distribution, holding, and use conform to
7	such index listing; and
8	"(B) such animal feed is manufactured at a site
9	for which there is in effect a license issued pursuant
10	to subsection $(m)(1)$ to manufacture such animal
11	feed.".
12	(J) Section 512(b)(3) of the Federal Food,
13	Drug, and Cosmetic Act is amended by striking
14	"under paragraph (1) or a request for an inves-
15	tigational exemption under subsection (j)" and
16	inserting "under paragraph (1), section 571, or
17	a request for an investigational exemption
18	under subsection (j)".
19	(K) Section $512(d)(4)$ of the Federal
20	Food, Drug, and Cosmetic Act is amended by
21	striking "have previously been separately ap-
22	proved" and inserting "have previously been
23	separately approved pursuant to an application
24	submitted under section $512(b)(1)$ ".

1	(L) Section $512(f)$ of the Federal Food,
2	Drug, and Cosmetic Act is amended by striking
3	"subsection (d), (e), or (m)" and inserting
4	"subsection (d), (e), or (m), or section 571 (c),
5	(d), or (e)".
6	(M) Section 512(g) of the Federal Food,
7	Drug, and Cosmetic Act is amended by striking
8	"this section" and inserting "this section, or
9	section 571".
10	(N) Section 512(i) of the Federal Food,
11	Drug, and Cosmetic Act is amended by striking
12	"subsection (b)" and inserting "subsection (b)
13	or section 571" and by inserting "or upon fail-
14	ure to renew a conditional approval under sec-
15	tion 571" after "or upon its suspension".
16	(O) Section $512(l)(1)$ of the Federal Food,
17	Drug, and Cosmetic Act is amended by striking
18	"subsection (b)" and inserting "subsection (b)
19	or section 571".
20	(P) Section $512(m)(1)(C)$ of the Federal
21	Food, Drug, and Cosmetic Act is amended by
22	striking "applicable regulations published pur-
23	suant to subsection (i)" and inserting "applica-
24	ble regulations published pursuant to subsection
25	(i) or for indexed new animal drugs in accord-

1	ance with the index listing published pursuant
2	to section $572(e)(2)$ and the labeling require-
3	ments set forth in section 572(h)".
4	(Q) Section $512(m)(3)$ of the Federal
5	Food, Drug, and Cosmetic Act is amended by
6	inserting "or an index listing pursuant to sec-
7	tion 572(e)" after "subsection (i)" each place it
8	appears.
9	(R) Section $512(p)(1)$ of the Federal Food,
10	Drug, and Cosmetic Act is amended by striking
11	"subsection $(b)(1)$ " and inserting "subsection
12	(b)(1) or section 571(a)".
13	(S) Section $512(p)(2)$ of the Federal Food,
14	Drug, and Cosmetic Act is amended by striking
15	"subsection $(b)(1)$ " and inserting "subsection
16	(b)(1) or section 571(a)".
17	(T) Section $108(b)(3)$ of Public Law 90–
18	399 is amended by striking "section $201(w)$ as
19	added by this Act" and inserting "section
20	201(v)".
21	(6) REGULATIONS.—On the date of enactment
22	of this Act, the Secretary of Health and Human
23	Services shall implement sections 571 and 573 of
24	the Federal Food, Drug, and Cosmetic Act and sub-
25	sequently publish implementing regulations. Not

1	later than 12 months after the date of enactment of
2	this Act, the Secretary shall issue proposed regula-
3	tions to implement section 573 of the Federal Food,
4	Drug, and Cosmetic Act (as added by this Act), and
5	not later than 24 months after the date of enact-
6	ment of this Act, the Secretary shall issue final reg-
7	ulations implementing section 573 of the Federal
8	Food, Drug, and Cosmetic Act. Not later than 18
9	months after the date of enactment of this Act, the
10	Secretary shall issue proposed regulations to imple-
11	ment section 572 of the Federal Food, Drug, and
12	Cosmetic Act (as added by this Act), and not later
13	than 36 months after the date of enactment of this
14	Act, the Secretary shall issue final regulations imple-
15	menting section 572 of the Federal Food, Drug, and
16	Cosmetic Act. Not later than 30 months after the
17	date of enactment of this Act, the Secretary shall
18	issue proposed regulations to implement section 571
19	of the Federal Food, Drug, and Cosmetic Act (as
20	added by this Act), and not later than 42 months
21	after the date of enactment of this Act, the Sec-
22	retary shall issue final regulations implementing sec-
23	tion 571 of the Federal Food, Drug, and Cosmetic
24	Act. These timeframes shall be extended by 12
25	months for each fiscal year, in which the funds au-

thorized to be appropriated under subsection (i) are
 not in fact appropriated.

3 (7) OFFICE.—The Secretary of Health and 4 Human Services shall establish within the Center for 5 Veterinary Medicine (of the Food and Drug Admin-6 istration), an Office of Minor Use and Minor Species 7 Animal Drug Development that reports directly to 8 the Director of the Center for Veterinary Medicine. 9 This office shall be responsible for overseeing the de-10 velopment and legal marketing of new animal drugs for minor uses and minor species. There is author-11 12 ized to be appropriated to carry out this subsection 13 \$1,200,000 for fiscal year 2004 and such sums as 14 may be necessary for each fiscal year thereafter.

15 (8)AUTHORIZATION OF APPROPRIATIONS.— 16 There is authorized to be appropriated to carry out 17 section 573(b) of the Federal Food, Drug, and Cos-18 metic Act (as added by this section) \$1,000,000 for 19 the fiscal year following publication of final imple-20 menting regulations, \$2,000,000 for the subsequent 21 fiscal year, and such sums as may be necessary for 22 each fiscal year thereafter.

40

TITLE II—FOOD ALLERGEN LA BELING AND CONSUMER PRO TECTION

4 SEC. 201. SHORT TITLE.

5 This title may be cited as the "Food Allergen Label-6 ing and Consumer Protection Act of 2004".

7 SEC. 202. FINDINGS.

8 Congress finds that—

9 (1) it is estimated that—

10 (A) approximately 2 percent of adults and
11 about 5 percent of infants and young children
12 in the United States suffer from food allergies;
13 and

(B) each year, roughly 30,000 individuals
require emergency room treatment and 150 individuals die because of allergic reactions to
food;

(2)(A) eight major foods or food groups—milk,
eggs, fish, Crustacean shellfish, tree nuts, peanuts,
wheat, and soybeans—account for 90 percent of
food allergies;

(B) at present, there is no cure for food aller-gies; and

24 (C) a food allergic consumer must avoid the25 food to which the consumer is allergic;

1	(3)(A) in a review of the foods of randomly se-
2	lected manufacturers of baked goods, ice cream, and
3	candy in Minnesota and Wisconsin in 1999, the
4	Food and Drug Administration found that 25 per-
5	cent of sampled foods failed to list peanuts or eggs
6	as ingredients on the food labels; and
7	(B) nationally, the number of recalls because of
8	unlabeled allergens rose to 121 in 2000 from about
9	35 a decade earlier;
10	(4) a recent study shows that many parents of
11	children with a food allergy were unable to correctly
12	identify in each of several food labels the ingredients
13	derived from major food allergens;
14	(5)(A) ingredients in foods must be listed by
15	their "common or usual name";
16	(B) in some cases, the common or usual name
17	of an ingredient may be unfamiliar to consumers,
18	and many consumers may not realize the ingredient
19	is derived from, or contains, a major food allergen;
20	and
21	(C) in other cases, the ingredients may be de-
22	clared as a class, including spices, flavorings, and
23	certain colorings, or are exempt from the ingredient
24	labeling requirements, such as incidental additives;
25	and

1	(6)(A) celiac disease is an immune-mediated
2	disease that causes damage to the gastrointestinal
3	tract, central nervous system, and other organs;
4	(B) the current recommended treatment is
5	avoidance of glutens in foods that are associated
6	with celiac disease; and
7	(C) a multicenter, multiyear study estimated
8	that the prevalence of celiac disease in the United
9	States is 0.5 to 1 percent of the general population.
10	SEC. 203. FOOD LABELING; REQUIREMENT OF INFORMA-
11	TION REGARDING ALLERGENIC SUBSTANCES.
12	(a) IN GENERAL.—Section 403 of the Federal Food,
13	Drug, and Cosmetic Act (21 U.S.C. 343) is amended by
14	adding at the end the following:
15	(w)(1) If it is not a raw agricultural commodity and
16	it is, or it contains an ingredient that bears or contains,
17	a major food allergen, unless either—
18	"(A) the word 'Contains', followed by the name
19	of the food source from which the major food aller-
20	gen is derived, is printed immediately after or is ad-
21	jacent to the list of ingredients (in a type size no
22	smaller than the type size used in the list of ingredi-
23	ents) required under subsections (g) and (i); or
24	"(B) the common or usual name of the major
25	food allergen in the list of ingredients required

44

1	under subsections (g) and (i) is followed in paren-
2	theses by the name of the food source from which
3	the major food allergen is derived, except that the
4	name of the food source is not required when—
5	"(i) the common or usual name of the in-
6	gredient uses the name of the food source from
7	which the major food allergen is derived; or
8	"(ii) the name of the food source from
9	which the major food allergen is derived ap-
10	pears elsewhere in the ingredient list, unless the
11	name of the food source that appears elsewhere
12	in the ingredient list appears as part of the
13	name of a food ingredient that is not a major
14	food allergen under section $201(qq)(2)(A)$ or
15	(B).
16	"(2) As used in this subsection, the term 'name of

10 (2) As used in this subsection, the term name of
17 the food source from which the major food allergen is de18 rived' means the name described in section 201(qq)(1);
19 provided that in the case of a tree nut, fish, or Crustacean
20 shellfish, the term 'name of the food source from which
21 the major food allergen is derived' means the name of the
22 specific type of nut or species of fish or Crustacean shell23 fish.

24 "(3) The information required under this subsection25 may appear in labeling in lieu of appearing on the label

only if the Secretary finds that such other labeling is suffi cient to protect the public health. A finding by the Sec retary under this paragraph (including any change in an
 earlier finding under this paragraph) is effective upon
 publication in the Federal Register as a notice.

6 "(4) Notwithstanding subsection (g), (i), or (k), or 7 any other law, a flavoring, coloring, or incidental additive 8 that is, or that bears or contains, a major food allergen 9 shall be subject to the labeling requirements of this sub-10 section.

11 "(5) The Secretary may by regulation modify the re-12 quirements of subparagraph (A) or (B) of paragraph (1), 13 or eliminate either the requirement of subparagraph (A) 14 or the requirements of subparagraph (B) of paragraph 15 (1), if the Secretary determines that the modification or elimination of the requirement of subparagraph (A) or the 16 requirements of subparagraph (B) is necessary to protect 17 the public health. 18

"(6)(A) Any person may petition the Secretary to exempt a food ingredient described in section 201(qq)(2)
from the allergen labeling requirements of this subsection.

"(B) The Secretary shall approve or deny such petition within 180 days of receipt of the petition or the petition shall be deemed denied, unless an extension of time

is mutually agreed upon by the Secretary and the peti tioner.

"(C) The burden shall be on the petitioner to provide
scientific evidence (including the analytical method used
to produce the evidence) that demonstrates that such food
ingredient, as derived by the method specified in the petition, does not cause an allergic response that poses a risk
to human health.

9 "(D) A determination regarding a petition under this10 paragraph shall constitute final agency action.

"(E) The Secretary shall promptly post to a public
site all petitions received under this paragraph within 14
days of receipt and the Secretary shall promptly post the
Secretary's response to each.

"(7)(A) A person need not file a petition under paragraph (6) to exempt a food ingredient described in section
201(qq)(2) from the allergen labeling requirements of this
subsection, if the person files with the Secretary a notification containing—

"(i) scientific evidence (including the analytical
method used) that demonstrates that the food ingredient (as derived by the method specified in the notification, where applicable) does not contain allergenic protein; or

"(ii) a determination by the Secretary that the
 ingredient does not cause an allergic response that
 poses a risk to human health under a premarket approval or notification program under section 409.

5 "(B) The food ingredient may be introduced or delivered for introduction into interstate commerce as a food 6 7 ingredient that is not a major food allergen 90 days after 8 the date of receipt of the notification by the Secretary, 9 unless the Secretary determines within the 90-day period that the notification does not meet the requirements of 10 this paragraph, or there is insufficient scientific evidence 11 12 to determine that the food ingredient does not contain al-13 lergenic protein or does not cause an allergenic response that poses a risk to human health. 14

"(C) The Secretary shall promptly post to a public
site all notifications received under this subparagraph
within 14 days of receipt and promptly post any objections
thereto by the Secretary.

19 "(x) Notwithstanding subsection (g), (i), or (k), or 20 any other law, a spice, flavoring, coloring, or incidental 21 additive that is, or that bears or contains, a food allergen 22 (other than a major food allergen), as determined by the 23 Secretary by regulation, shall be disclosed in a manner 24 specified by the Secretary by regulation.".

1	(b) Effect on Other Authority.—The amend-
2	ments made by this section that require a label or labeling
3	for major food allergens do not alter the authority of the
4	Secretary of Health and Human Services under the Fed-
5	eral Food, Drug, and Cosmetic Act (21 U.S.C. 301 et
6	seq.) to require a label or labeling for other food allergens.
7	(c) Conforming Amendments.—
8	(1) Section 201 of the Federal Food, Drug, and
9	Cosmetic Act (21 U.S.C. 321) (as amended by sec-
10	tion 102(b)) is amended by adding at the end the
11	following:
12	"(qq) The term 'major food allergen' means any of
13	the following:
14	"(1) Milk, egg, fish (e.g., bass, flounder, or
15	cod), Crustacean shellfish (e.g., crab, lobster, or
16	shrimp), tree nuts (e.g., almonds, pecans, or wal-
17	nuts), wheat, peanuts, and soybeans.
18	((2) A food ingredient that contains protein de-
19	rived from a food specified in paragraph (1), except
20	the following:
21	"(A) Any highly refined oil derived from a
22	food specified in paragraph (1) and any ingre-
22 23	food specified in paragraph (1) and any ingre- dient derived from such highly refined oil.

48

† S 741 ES

(2) Section 403A(a)(2) of the Federal Food,
 Drug, and Cosmetic Act (21 U.S.C. 343-1(a)(2)) is
 amended by striking "or 403(i)(2)" and inserting
 "403(i)(2), 403(w), or 403(x)".

5 (d) EFFECTIVE DATE.—The amendments made by
6 this section shall apply to any food that is labeled on or
7 after January 1, 2006.

8 SEC. 204. REPORT ON FOOD ALLERGENS.

9 Not later than 18 months after the date of enactment 10 of this Act, the Secretary of Health and Human Services 11 (in this section referred to as the "Secretary") shall sub-12 mit to the Committee on Health, Education, Labor, and 13 Pensions of the Senate and the Committee on Energy and 14 Commerce of the House of Representatives a report 15 that—

16 (1)(A) analyzes—

17 (i) the ways in which foods, during manu-18 facturing and processing, are unintentionally 19 contaminated with major food allergens, includ-20 ing contamination caused by the use by manu-21 facturers of the same production line to produce 22 both products for which major food allergens 23 are intentional ingredients and products for 24 which major food allergens are not intentional 25 ingredients; and

1	(ii) the ways in which foods produced on
2	dedicated production lines are unintentionally
3	contaminated with major food allergens; and
4	(B) estimates how common the practices de-
5	scribed in subparagraph (A) are in the food indus-
6	try, with breakdowns by food type as appropriate;
7	(2) advises whether good manufacturing prac-
8	tices or other methods can be used to reduce or
9	eliminate cross-contact of foods with the major food
10	allergens;
11	(3) describes—
12	(A) the various types of advisory labeling
13	(such as labeling that uses the words "may con-
14	tain") used by food producers;
15	(B) the conditions of manufacture of food
16	that are associated with the various types of ad-
17	visory labeling; and
18	(C) the extent to which advisory labels are
19	being used on food products;
20	(4) describes how consumers with food allergies
21	or the caretakers of consumers would prefer that in-
22	formation about the risk of cross-contact be commu-
23	nicated on food labels as determined by using appro-
24	priate survey mechanisms;

1	(5) states the number of inspections of food
2	manufacturing and processing facilities conducted in
3	the previous 2 years and describes—
4	(A) the number of facilities and food labels
5	that were found to be in compliance or out of
6	compliance with respect to cross-contact of
7	foods with residues of major food allergens and
8	the proper labeling of major food allergens;
9	(B) the nature of the violations found; and
10	(C) the number of voluntary recalls, and
11	their classifications, of foods containing
12	undeclared major food allergens; and
13	(6) assesses the extent to which the Secretary
14	and the food industry have effectively addressed
15	cross-contact issues.
16	SEC. 205. INSPECTIONS RELATING TO FOOD ALLERGENS.
17	The Secretary of Health and Human Services shall
18	conduct inspections consistent with the authority under
19	section 704 of the Federal Food, Drug, and Cosmetic Act
20	(21 U.S.C. 374) of facilities in which foods are manufac-
21	tured, processed, packed, or held—

(1) to ensure that the entities operating the facilities comply with practices to reduce or eliminate
cross-contact of a food with residues of major food

allergens that are not intentional ingredients of the
 food; and

3 (2) to ensure that major food allergens are4 properly labeled on foods.

5 SEC. 206. GLUTEN LABELING.

6 Not later than 2 years after the date of enactment 7 of this Act, the Secretary of Health and Human Services, 8 in consultation with appropriate experts and stakeholders, 9 shall issue a proposed rule to define, and permit use of, the term "gluten-free" on the labeling of foods. Not later 10 than 4 years after the date of enactment of this Act, the 11 12 Secretary shall issue a final rule to define, and permit use of, the term "gluten-free" on the labeling of foods. 13

14 SEC. 207. IMPROVEMENT AND PUBLICATION OF DATA ON 15 FOOD-RELATED ALLERGIC RESPONSES.

(a) IN GENERAL.—The Secretary of Health and
Human Services, acting through the Director of the Centers for Disease Control and Prevention and in consultation with the Commissioner of Food and Drugs, shall improve (including by educating physicians and other health
care providers) the collection of, and publish as it becomes
available, national data on—

23 (1) the prevalence of food allergies;

24 (2) the incidence of clinically significant or seri25 ous adverse events related to food allergies; and

(3) the use of different modes of treatment for
 and prevention of allergic responses to foods.

3 (b) AUTHORIZATION OF APPROPRIATIONS.—For the
4 purpose of carrying out this section, there are authorized
5 to be appropriated such sums as may be necessary.

6 SEC. 208. FOOD ALLERGIES RESEARCH.

7 (a) IN GENERAL.—The Secretary of Health and 8 Human Services, acting through the Director of the Na-9 tional Institutes of Health, shall convene an ad hoc panel 10 of nationally recognized experts in allergy and immunology 11 to review current basic and clinical research efforts related 12 to food allergies.

(b) RECOMMENDATIONS.—Not later than 1 year
after the date of enactment of this Act, the panel shall
make recommendations to the Secretary for enhancing
and coordinating research activities concerning food allergies, which the Secretary shall make public.

18 SEC. 209. FOOD ALLERGENS IN THE FOOD CODE.

19 The Secretary of Health and Human Services shall, 20 in the Conference for Food Protection, as part of its ef-21 forts to encourage cooperative activities between the 22 States under section 311 of the Public Health Service Act 23 (42 U.S.C. 243), pursue revision of the Food Code to pro-24 vide guidelines for preparing allergen-free foods in food 25 establishments, including in restaurants, grocery store delicatessens and bakeries, and elementary and secondary
 school cafeterias. The Secretary shall consider guidelines
 and recommendations developed by public and private en tities for public and private food establishments for pre paring allergen-free foods in pursuing this revision.


6 SEC. 210. RECOMMENDATIONS REGARDING RESPONDING 7 TO FOOD-RELATED ALLERGIC RESPONSES.

8 The Secretary of Health and Human Services shall, 9 in providing technical assistance relating to trauma care 10 and emergency medical services to State and local agencies 11 under section 1202(b)(3) of the Public Health Service Act 12 (42 U.S.C. 300d–2(b)(3)), include technical assistance re-13 lating to the use of different modes of treatment for and 14 prevention of allergic responses to foods.

Passed the Senate March 8, 2004.

Attest:

Secretary.



AN ACT

To amend the Federal Food, Drug, and Cosmetic Act with regard to new animal drugs, and for other purposes.